Lixte Biotech Hlds (LIXT)

$3.97 -0.25 (-5.92%)
Market Cap 11.33M
Revenue (ttm) 0.00
Net Income (ttm) -3.59M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 831,600
Avg Vol 2,499,268
Day's Range N/A - N/A
Shares Out 2.68M
Stochastic %K 87%
Beta 0.31
Analysts Strong Buy
Price Target N/A

Company Profile

Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company's LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion; and LB-100 combined with dostarlimab t...

Industry: Biotechnology
Sector: Healthcare
Phone: 631 830 7092
Fax: 631 982 5050
Website: lixte.com
Address:
680 East Colorado Boulevard, Suite 180, Pasadena, United States
StockScanners
StockScanners Jul. 12 at 7:29 AM
$LIXT we reached 4.45, lets go teamm, another great idea, be ready for next idea
0 · Reply
PaulLaurent
PaulLaurent Jul. 11 at 6:59 PM
📍🧨 Highest Borrow Fee Update 🔐📍 $SONM $LIXT $BMNR $OP $SLRX
1 · Reply
_www_larval_com_
_www_larval_com_ Jul. 11 at 5:07 PM
$LIXT just reverted 5% higher to -6% (~574Kv) a few minutes ago, follow for more volatility.
0 · Reply
MajorStockTradingLLC
MajorStockTradingLLC Jul. 11 at 3:10 PM
$LIXT This guy Stock Catcher thoughts?
0 · Reply
part_time_trader
part_time_trader Jul. 11 at 2:10 PM
$LIXT I'm glad I hold on to this ticker and didn't sell last time it shoot up.
0 · Reply
ACInvestorBlog
ACInvestorBlog Jul. 11 at 12:52 PM
$LIXT Form 8K https://ir.lixte.com/sec-filings/all-sec-filings/content/0001641172-25-018684/form8-k.htm "Lixte Biotechnology Holdings, Inc. (the “Company”) issued a press release announcing that the Medical Journal Nature published findings by a team of physician scientists that validate the scientific premise underlying the Company’s ongoing clinical trials for Ovarian and Colorectal cancers. A copy of the press release is filed as Exhibit 99.1 hereto and is incorporated by reference." Market cap is just $12M
0 · Reply
DavidScott
DavidScott Jul. 11 at 2:25 AM
On watch tomorrow (swing trading) // Part 2 🔥📈📚 $LIXT $SIDU $HOLO $AMC $GME
3 · Reply
SadyK189
SadyK189 Jul. 10 at 10:06 PM
$LIXT Price 2.31. My post was "LIXT is consolidating on daily chart. Key support at 2 - 2.25. It can test 3 - 3.30 zone again. Currently at 2.31" It hit our desired zone, went till 4.30 today
0 · Reply
Stock_Catcher
Stock_Catcher Jul. 10 at 9:12 PM
$LIXT ripping face
0 · Reply
JFZ
JFZ Jul. 10 at 8:25 PM
$BTCM $HOLO $LIXT $SAFX $SIDU
0 · Reply
Latest News on LIXT
Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.'s $1.5 Million Registered Direct Offering

Jul 9, 2025, 5:15 PM EDT - 2 days ago

Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.'s $1.5 Million Registered Direct Offering

New Clinical Findings Published in Scientific Journal Nature Validate LIXTE's Ongoing Ovarian and Colorectal Cancer Trials

Jul 9, 2025, 8:05 AM EDT - 2 days ago

New Clinical Findings Published in Scientific Journal Nature Validate LIXTE's Ongoing Ovarian and Colorectal Cancer Trials

Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.'s $5.0 Million Private Placement

Jul 8, 2025, 2:57 PM EDT - 3 days ago

Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.'s $5.0 Million Private Placement

Lixte Biotechnology Holdings, Inc. Announces the Closing of $5.0 Million Private Placement Priced at the Market

Jul 2, 2025, 4:05 PM EDT - 9 days ago

Lixte Biotechnology Holdings, Inc. Announces the Closing of $5.0 Million Private Placement Priced at the Market

Lixte Biotechnology Holdings, Inc. Announces $5.0 Million Private Placement Priced at the Market

Jul 1, 2025, 4:15 PM EDT - 10 days ago

Lixte Biotechnology Holdings, Inc. Announces $5.0 Million Private Placement Priced at the Market

LIXTE Launches New Study to Determine if Certain Pre-Cancerous Cells Found in an Aging Population Can Be Eliminated by LB-100

Mar 31, 2025, 8:30 AM EDT - 3 months ago

LIXTE Launches New Study to Determine if Certain Pre-Cancerous Cells Found in an Aging Population Can Be Eliminated by LB-100

LIXTE Biotechnology Provides Update On Progress with Proprietary Compound, LB-100, to Treat Ovarian and Colorectal Cancer

Mar 27, 2025, 8:30 AM EDT - 3 months ago

LIXTE Biotechnology Provides Update On Progress with Proprietary Compound, LB-100, to Treat Ovarian and Colorectal Cancer

LIXTE Adds Northwestern University's Lurie Cancer Center as Second Site in Ongoing Clinical Trial for Ovarian Clear Cell Cancer

Feb 25, 2025, 8:30 AM EST - 4 months ago

LIXTE Adds Northwestern University's Lurie Cancer Center as Second Site in Ongoing Clinical Trial for Ovarian Clear Cell Cancer

LIXTE Biotechnology Announces Closing of $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Feb 13, 2025, 10:35 AM EST - 5 months ago

LIXTE Biotechnology Announces Closing of $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

LIXTE Biotechnology Announces $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Feb 11, 2025, 8:42 AM EST - 5 months ago

LIXTE Biotechnology Announces $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

LIXTE Biotechnology Submits Request for Withdrawal of Form S-1 Registration Statement

Feb 10, 2025, 5:00 PM EST - 5 months ago

LIXTE Biotechnology Submits Request for Withdrawal of Form S-1 Registration Statement

LIXTE Receives U.S. Patent Issue Notification for Immune Oncology

Sep 4, 2024, 8:30 AM EDT - 11 months ago

LIXTE Receives U.S. Patent Issue Notification for Immune Oncology

First Patient Dosed with LIXTE's LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma Company

Aug 26, 2024, 8:30 AM EDT - 11 months ago

First Patient Dosed with LIXTE's LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma Company

LIXTE Biotechnology Provides Update On Recent Activities and Developments

Aug 19, 2024, 8:30 AM EDT - 11 months ago

LIXTE Biotechnology Provides Update On Recent Activities and Developments

LIXTE Biotechnology Holdings to Present at Two Investor Conferences

Aug 15, 2024, 8:30 AM EDT - 11 months ago

LIXTE Biotechnology Holdings to Present at Two Investor Conferences

Lixte Biotechnology Holdings, Inc. to Present at August 20th Virtual Investor Summit Microcap Event

Aug 14, 2024, 10:50 PM EDT - 11 months ago

Lixte Biotechnology Holdings, Inc. to Present at August 20th Virtual Investor Summit Microcap Event

LIXTE Biotechnology Holdings announces collaboration on a New Colon Cancer Clinical Trial

Jun 14, 2024, 11:00 AM EDT - 1 year ago

LIXTE Biotechnology Holdings announces collaboration on a New Colon Cancer Clinical Trial

LIXTE Biotechnology Holdings to Collaborate with Roche and Netherlands Cancer Institute in New Colon Cancer Clinical Trial

Jun 14, 2024, 9:30 AM EDT - 1 year ago

LIXTE Biotechnology Holdings to Collaborate with Roche and Netherlands Cancer Institute in New Colon Cancer Clinical Trial

Scientific Journal Reports Findings that Show LIXTE's Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune System

Jun 6, 2024, 8:30 AM EDT - 1 year ago

Scientific Journal Reports Findings that Show LIXTE's Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune System

LIXTE Biotechnology Holdings Names Distinguished Oncologist Jan Schellens as Chief Medical Officer

Jun 3, 2024, 8:30 AM EDT - 1 year ago

LIXTE Biotechnology Holdings Names Distinguished Oncologist Jan Schellens as Chief Medical Officer

LIXTE Biotechnology Holdings Provides Update on Recent Activities

May 20, 2024, 8:30 AM EDT - 1 year ago

LIXTE Biotechnology Holdings Provides Update on Recent Activities

LIXTE Biotechnology Co-Sponsoring International Scientific Conference on “Therapeutic Over-Activation in Cancer”

May 8, 2024, 9:25 AM EDT - 1 year ago

LIXTE Biotechnology Co-Sponsoring International Scientific Conference on “Therapeutic Over-Activation in Cancer”

LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments

Mar 21, 2024, 8:30 AM EDT - 1 year ago

LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments

Professor René Bernards to Present New Pre-Clinical Data on LIXTE's LB-100 at Joint Conference of European and American Associations for Cancer Research

Feb 27, 2024, 8:30 AM EST - 1 year ago

Professor René Bernards to Present New Pre-Clinical Data on LIXTE's LB-100 at Joint Conference of European and American Associations for Cancer Research

LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI

Feb 26, 2024, 8:30 AM EST - 1 year ago

LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI

First Patient Dosed with LIXTE's LB-100 and GSK's Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma Trial

Jan 29, 2024, 8:30 AM EST - 1 year ago

First Patient Dosed with LIXTE's LB-100 and GSK's Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma Trial

LIXTE Biotechnology Provides Update on Clinical Progress and Expanding Collaborations

Nov 13, 2023, 8:30 AM EST - 1 year ago

LIXTE Biotechnology Provides Update on Clinical Progress and Expanding Collaborations

LIXTE Biotechnology Holdings Announces the Passing of its Founder, John S. Kovach

Oct 9, 2023, 8:30 AM EDT - 1 year ago

LIXTE Biotechnology Holdings Announces the Passing of its Founder, John S. Kovach

LIXTE Appoints Bas van der Baan as President and Chief Executive Officer

Sep 26, 2023, 8:30 AM EDT - 1 year ago

LIXTE Appoints Bas van der Baan as President and Chief Executive Officer

LIXTE Biotechnology Announces a Supported Collaborative Trial to Study LIXTE's First-in-Class PP2A Inhibitor, LB-100, Plus GSK's Immunotherapy, Dostarlimab, in Clear-Cell Ovarian Cancer

Sep 20, 2023, 8:30 AM EDT - 1 year ago

LIXTE Biotechnology Announces a Supported Collaborative Trial to Study LIXTE's First-in-Class PP2A Inhibitor, LB-100, Plus GSK's Immunotherapy, Dostarlimab, in Clear-Cell Ovarian Cancer

LIXTE Biotechnology Announces Closing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules

Jul 20, 2023, 4:05 PM EDT - 2 years ago

LIXTE Biotechnology Announces Closing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules

LIXTE Biotechnology Holdings, Inc. Regains Compliance with Nasdaq Continued Listing Requirements

Jun 23, 2023, 8:30 AM EDT - 2 years ago

LIXTE Biotechnology Holdings, Inc. Regains Compliance with Nasdaq Continued Listing Requirements

LIXTE Biotechnology and the Spanish Sarcoma Group Enroll First Patient in a Phase 1b/2 Randomized Trial of Doxorubicin +/- LIXTE's Lead Anti-Cancer Compound, LB-100, in Advanced Soft Tissue Sarcomas

Jun 7, 2023, 8:30 AM EDT - 2 years ago

LIXTE Biotechnology and the Spanish Sarcoma Group Enroll First Patient in a Phase 1b/2 Randomized Trial of Doxorubicin +/- LIXTE's Lead Anti-Cancer Compound, LB-100, in Advanced Soft Tissue Sarcomas

LIXTE Biotechnology Holdings, Inc. Announces 1-for-10 Reverse Stock Split of its Common Stock Effective on Pre-Market Opening on June 5, 2023

Jun 2, 2023, 12:30 PM EDT - 2 years ago

LIXTE Biotechnology Holdings, Inc. Announces 1-for-10 Reverse Stock Split of its Common Stock Effective on Pre-Market Opening on June 5, 2023

Recently Published Independent Research Reveals New Mechanisms by Which LIXTE Biotechnology's Lead Clinical Compound, LB-100, Increases Effectiveness of Cancer Immunotherapy

May 30, 2023, 8:30 AM EDT - 2 years ago

Recently Published Independent Research Reveals New Mechanisms by Which LIXTE Biotechnology's Lead Clinical Compound, LB-100, Increases Effectiveness of Cancer Immunotherapy

LIXTE Biotechnology Reports First Spanish Site Activated to Begin Accrual of Patients for a Phase 1b/2 Clinical Trial of LIXTE's Lead Anti-Cancer Compound, LB-100, Added to Doxorubicin as First-Line Treatment of Advanced Soft Tissue Sarcoma

Apr 24, 2023, 8:30 AM EDT - 2 years ago

LIXTE Biotechnology Reports First Spanish Site Activated to Begin Accrual of Patients for a Phase 1b/2 Clinical Trial of LIXTE's Lead Anti-Cancer Compound, LB-100, Added to Doxorubicin as First-Line Treatment of Advanced Soft Tissue Sarcoma

LIXTE Biotechnology Announces Sarah Cannon Research Institute Joins City of Hope's Ongoing Phase 1b Clinical Trial in Evaluating Lixte's Lead Anti-Cancer Compound, LB-100, in Small Cell Lung Cancer

Apr 4, 2023, 8:30 AM EDT - 2 years ago

LIXTE Biotechnology Announces Sarah Cannon Research Institute Joins City of Hope's Ongoing Phase 1b Clinical Trial in Evaluating Lixte's Lead Anti-Cancer Compound, LB-100, in Small Cell Lung Cancer

LIXTE BIOTECHNOLOGY HOLDINGS REPORTS NEWLY PUBLISHED INDEPENDENT PRE-CLINICAL RESEARCH

Feb 14, 2023, 1:50 PM EST - 2 years ago

LIXTE BIOTECHNOLOGY HOLDINGS REPORTS NEWLY PUBLISHED INDEPENDENT PRE-CLINICAL RESEARCH

LIXTE BIOTECHNOLOGY HOLDINGS, INC. REPORTS THAT ITS LEAD CLINICAL COMPOUND, LB-100, CAN KILL CANCER CELLS THROUGH HYPER-STIMULATION OF CELL PROLIFERATION SIGNALS IN PRE-CLINICAL MODELS

Feb 7, 2023, 12:16 PM EST - 2 years ago

LIXTE BIOTECHNOLOGY HOLDINGS, INC. REPORTS THAT ITS LEAD CLINICAL COMPOUND, LB-100, CAN KILL CANCER CELLS THROUGH HYPER-STIMULATION OF CELL PROLIFERATION SIGNALS IN PRE-CLINICAL MODELS

LIXTE Biotechnology Holdings to Present at Planet MicroCap Showcase: VIRTUAL 2022 Investor Conference

Nov 30, 2022, 8:05 AM EST - 2 years ago

LIXTE Biotechnology Holdings to Present at Planet MicroCap Showcase: VIRTUAL 2022 Investor Conference

LIXTE BIOTECHNOLOGY ANNOUNCES APPROVAL OF A PHASE 1B/2 RANDOMIZED TRIAL OF DOXORUBICIN +/-LB-100 IN ADVANCED SOFT TISSUE SARCOMAS TO BE CONDUCTED BY THE SPANISH SARCOMA GROUP

Oct 13, 2022, 8:30 AM EDT - 2 years ago

LIXTE BIOTECHNOLOGY ANNOUNCES APPROVAL OF A PHASE 1B/2 RANDOMIZED TRIAL OF DOXORUBICIN +/-LB-100 IN ADVANCED SOFT TISSUE SARCOMAS TO BE CONDUCTED BY THE SPANISH SARCOMA GROUP

LIXTE BIOTECHNOLOGY ANNOUNCES APPOINTMENT OF BAS VAN DER BAAN, INTERNATIONALLY RECOGNIZED BIOTECH BUSINESS DEVELOPMENT EXECUTIVE, TO ITS BOARD OF DIRECTORS

Jun 21, 2022, 8:30 AM EDT - 3 years ago

LIXTE BIOTECHNOLOGY ANNOUNCES APPOINTMENT OF BAS VAN DER BAAN, INTERNATIONALLY RECOGNIZED BIOTECH BUSINESS DEVELOPMENT EXECUTIVE, TO ITS BOARD OF DIRECTORS

LIXTE BIOTECHNOLOGY ANNOUNCES APPOINTMENT OF PROFESSOR RENÉ BERNARDS TO ITS BOARD OF DIRECTORS

Jun 15, 2022, 8:30 AM EDT - 3 years ago

LIXTE BIOTECHNOLOGY ANNOUNCES APPOINTMENT OF PROFESSOR RENÉ BERNARDS TO ITS BOARD OF DIRECTORS

5 Short Squeeze Candidates To Watch This Week: Aterian, Harbor Custom Development Remain At The Top, Veru Joins

May 2, 2022, 10:45 AM EDT - 3 years ago

5 Short Squeeze Candidates To Watch This Week: Aterian, Harbor Custom Development Remain At The Top, Veru Joins

ATER VERU ZYME

LIXTE Biotechnology Announces the Closing of $5.8 Million Registered Direct Offering Priced At-The-Market

Apr 14, 2022, 6:45 PM EDT - 3 years ago

LIXTE Biotechnology Announces the Closing of $5.8 Million Registered Direct Offering Priced At-The-Market

WallachBeth Capital Announces Completion of LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT) $5.8 Million Registered Direct Offering

Apr 14, 2022, 2:54 PM EDT - 3 years ago

WallachBeth Capital Announces Completion of LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT) $5.8 Million Registered Direct Offering

WestPark Capital Announces Completion of $5.8 Million Registered Direct Offering Priced At-The-Market for Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT)

Apr 13, 2022, 9:00 AM EDT - 3 years ago

WestPark Capital Announces Completion of $5.8 Million Registered Direct Offering Priced At-The-Market for Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT)

WallachBeth Capital Announces Purchase and Sale of LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT)

Apr 13, 2022, 8:30 AM EDT - 3 years ago

WallachBeth Capital Announces Purchase and Sale of LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT)

LIXTE Biotechnology Announces $5.8 Million Registered Direct Offering Priced At-The-Market

Apr 12, 2022, 1:53 PM EDT - 3 years ago

LIXTE Biotechnology Announces $5.8 Million Registered Direct Offering Priced At-The-Market

Lixte Biotech Shares Jumps Over 100% On Promising Preclinical Data From Lead Program In KRAS-Mutant Cancers

Apr 12, 2022, 9:32 AM EDT - 3 years ago

Lixte Biotech Shares Jumps Over 100% On Promising Preclinical Data From Lead Program In KRAS-Mutant Cancers

StockScanners
StockScanners Jul. 12 at 7:29 AM
$LIXT we reached 4.45, lets go teamm, another great idea, be ready for next idea
0 · Reply
PaulLaurent
PaulLaurent Jul. 11 at 6:59 PM
📍🧨 Highest Borrow Fee Update 🔐📍 $SONM $LIXT $BMNR $OP $SLRX
1 · Reply
_www_larval_com_
_www_larval_com_ Jul. 11 at 5:07 PM
$LIXT just reverted 5% higher to -6% (~574Kv) a few minutes ago, follow for more volatility.
0 · Reply
MajorStockTradingLLC
MajorStockTradingLLC Jul. 11 at 3:10 PM
$LIXT This guy Stock Catcher thoughts?
0 · Reply
part_time_trader
part_time_trader Jul. 11 at 2:10 PM
$LIXT I'm glad I hold on to this ticker and didn't sell last time it shoot up.
0 · Reply
ACInvestorBlog
ACInvestorBlog Jul. 11 at 12:52 PM
$LIXT Form 8K https://ir.lixte.com/sec-filings/all-sec-filings/content/0001641172-25-018684/form8-k.htm "Lixte Biotechnology Holdings, Inc. (the “Company”) issued a press release announcing that the Medical Journal Nature published findings by a team of physician scientists that validate the scientific premise underlying the Company’s ongoing clinical trials for Ovarian and Colorectal cancers. A copy of the press release is filed as Exhibit 99.1 hereto and is incorporated by reference." Market cap is just $12M
0 · Reply
DavidScott
DavidScott Jul. 11 at 2:25 AM
On watch tomorrow (swing trading) // Part 2 🔥📈📚 $LIXT $SIDU $HOLO $AMC $GME
3 · Reply
SadyK189
SadyK189 Jul. 10 at 10:06 PM
$LIXT Price 2.31. My post was "LIXT is consolidating on daily chart. Key support at 2 - 2.25. It can test 3 - 3.30 zone again. Currently at 2.31" It hit our desired zone, went till 4.30 today
0 · Reply
Stock_Catcher
Stock_Catcher Jul. 10 at 9:12 PM
$LIXT ripping face
0 · Reply
JFZ
JFZ Jul. 10 at 8:25 PM
$BTCM $HOLO $LIXT $SAFX $SIDU
0 · Reply
IntraTrades
IntraTrades Jul. 10 at 8:17 PM
$ABVE 274.31% $QTTB 103.68% $SQNS 82.24% $PTHS 55.76% $LIXT 53.45%
0 · Reply
DavidScott
DavidScott Jul. 10 at 8:06 PM
$BTCM $SAFX $LIXT $SIDU $HOLO = Great work everyone! The bulls had some nice movers today. These were our main trades, and we are bullish and expecting even more momentum on these names again going into Friday. If you need any guidance or a mentor, then feel free to join our team anytime! ✅🙌 Have a great day everybody! 🎉
0 · Reply
topstockalerts
topstockalerts Jul. 10 at 8:05 PM
Top Gainers PT2 $STKH $PTHS $MTEN $GIBO $LIXT
0 · Reply
DarthGoat
DarthGoat Jul. 10 at 7:54 PM
$ANTE $LIXT Day summary: Profit on sold positions: $1,155 – Left on the table for selling too early: $1,450
1 · Reply
vanguard100
vanguard100 Jul. 10 at 7:49 PM
$LIXT When Vanguard speaks, just listen... Easy 40%..
0 · Reply
Humble2281
Humble2281 Jul. 10 at 7:20 PM
$LIXT congrats to my peeps and nice green movement
0 · Reply
StockBoyAri
StockBoyAri Jul. 10 at 6:59 PM
$LIXT 🤗🤗🤗
0 · Reply
DarthGoat
DarthGoat Jul. 10 at 6:54 PM
$LIXT If you had been one of my followers on July 3rd, you would have entered this stock at $2.89 — and you probably wouldn’t have sold too quickly like I did, and you'd be up 37% right now.
0 · Reply
theshortsqueezer2022
theshortsqueezer2022 Jul. 10 at 6:41 PM
$LIXT squeezing like a champ
0 · Reply
suspendFlow
suspendFlow Jul. 10 at 6:40 PM
$LIXT sell it for 200m Do it for epic justice!
0 · Reply
Vermontgal
Vermontgal Jul. 10 at 6:30 PM
$LIXT too easy 😂
0 · Reply
theshortsqueezer2022
theshortsqueezer2022 Jul. 10 at 6:17 PM
$LIXT patience pays
0 · Reply